Open-label Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-type Transthyretin (Ttr) Amyloid Cardiomyopathy

Trial Profile

Open-label Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-type Transthyretin (Ttr) Amyloid Cardiomyopathy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs Tafamidis meglumine (Primary)
  • Indications Cardiomyopathies; Heart failure
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 13 Sep 2017 Planned End Date changed from 31 Dec 2021 to 1 Dec 2021.
    • 13 Sep 2017 Planned primary completion date changed from 31 Dec 2021 to 1 Dec 2021.
    • 19 Oct 2016 Status changed from suspended to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top